000153230 001__ 153230
000153230 005__ 20240229123042.0
000153230 0247_ $$2doi$$a10.1016/j.ejca.2019.11.021
000153230 0247_ $$2pmid$$apmid:31972396
000153230 0247_ $$2ISSN$$a0014-2964
000153230 0247_ $$2ISSN$$a0959-8049
000153230 0247_ $$2ISSN$$a1879-0852
000153230 0247_ $$2ISSN$$a1879-2995
000153230 0247_ $$2altmetric$$aaltmetric:74433146
000153230 037__ $$aDKFZ-2020-00263
000153230 041__ $$aeng
000153230 082__ $$a610
000153230 1001_ $$0P:(DE-He78)ac7aed57f26354e8a484b5d257f7bada$$aBhardwaj, Megha$$b0$$eFirst author$$udkfz
000153230 245__ $$aMultiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer.
000153230 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2020
000153230 3367_ $$2DRIVER$$aarticle
000153230 3367_ $$2DataCite$$aOutput Types/Journal article
000153230 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601300132_20614
000153230 3367_ $$2BibTeX$$aARTICLE
000153230 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153230 3367_ $$00$$2EndNote$$aJournal Article
000153230 500__ $$a#EA:C120#LA:C120#
000153230 520__ $$aBlood-based protein biomarker signatures might be an alternative or supplement to existing methods for early detection of colorectal cancer (CRC) for population-based screening. The objective of this study was to derive a protein biomarker signature for early detection of CRC and its precursor advanced adenoma (AA). In a two-stage design, 270 protein markers were measured by liquid chromatography/multiple reaction monitoring/mass spectrometry in plasma samples of discovery and validation sets. In the discovery set consisting of 100 newly diagnosed CRC cases and 100 age- and sex-matched controls free of neoplasm at screening colonoscopy, the algorithms predicting the presence of early- or late-stage CRC were derived by Lasso regression and .632 + bootstrap. The prediction algorithms were then externally validated in an independent validation set consisting of participants of screening colonoscopy including 56 participants with CRC, 99 with AA and 99 controls without any colorectal neoplasms. Three different signatures for all-, early- and late-stage CRC consisting of five-, three- and eight-protein markers were obtained in the discovery set with areas under the curves (AUCs) after .632 + bootstrap adjustment of 0.85, 0.83 and 0.96, respectively. External validation in the representative screening population yielded AUCs of 0.79 (95% CI, 0.70-0.86), 0.79 (95% CI, 0.66-0.89) and 0.80 (95% CI, 0.70-0.89) for all-, early- and late-stage CRCs, respectively. The three-marker early-stage algorithm yielded an AUC of 0.65 (95% CI, 0.56-0.73) for detection of AA in the validation set. Although not yet competitive with available stool-based tests for CRC early detection, the identified proteins may contribute to the development of powerful blood-based tests for early detection of CRC and its precursors AAs.
000153230 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000153230 588__ $$aDataset connected to CrossRef, PubMed,
000153230 7001_ $$0P:(DE-He78)f4e98340e600f7411886c21c7b778d36$$aWeigl, Korbinian$$b1$$udkfz
000153230 7001_ $$0P:(DE-He78)eabbefb821cdb73961a5adf967330b62$$aTikk, Kaja$$b2
000153230 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b3$$udkfz
000153230 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b4$$udkfz
000153230 7001_ $$aBorchers, Christoph H$$b5
000153230 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6$$eLast author$$udkfz
000153230 773__ $$0PERI:(DE-600)1468190-0$$a10.1016/j.ejca.2019.11.021$$gVol. 127, p. 30 - 40$$p30 - 40$$tEuropean journal of cancer$$v127$$x0959-8049$$y2020
000153230 909CO $$ooai:inrepo02.dkfz.de:153230$$pVDB
000153230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ac7aed57f26354e8a484b5d257f7bada$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000153230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4e98340e600f7411886c21c7b778d36$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000153230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)eabbefb821cdb73961a5adf967330b62$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000153230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000153230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000153230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000153230 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000153230 9141_ $$y2020
000153230 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000153230 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153230 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153230 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153230 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CANCER : 2017
000153230 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000153230 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000153230 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153230 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000153230 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153230 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153230 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000153230 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000153230 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000153230 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J CANCER : 2017
000153230 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000153230 9200_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000153230 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000153230 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000153230 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000153230 980__ $$ajournal
000153230 980__ $$aVDB
000153230 980__ $$aI:(DE-He78)C120-20160331
000153230 980__ $$aI:(DE-He78)C070-20160331
000153230 980__ $$aI:(DE-He78)HD01-20160331
000153230 980__ $$aUNRESTRICTED